Vise Technologies Inc. Purchases New Position in Stryker Corporation $SYK

Vise Technologies Inc. acquired a new position in shares of Stryker Corporation (NYSE:SYK) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 6,365 shares of the medical technology company’s stock, valued at approximately $2,518,000.

Other hedge funds have also recently added to or reduced their stakes in the company. United Services Automobile Association acquired a new position in shares of Stryker during the first quarter valued at about $2,857,000. Hendley & Co. Inc. grew its stake in Stryker by 60.3% in the second quarter. Hendley & Co. Inc. now owns 14,018 shares of the medical technology company’s stock valued at $5,546,000 after acquiring an additional 5,274 shares during the period. AXS Investments LLC increased its holdings in shares of Stryker by 13.7% during the first quarter. AXS Investments LLC now owns 8,827 shares of the medical technology company’s stock valued at $3,286,000 after acquiring an additional 1,062 shares in the last quarter. Park Edge Advisors LLC bought a new position in shares of Stryker in the 2nd quarter worth $679,000. Finally, Motco grew its position in Stryker by 3,157.8% in the 2nd quarter. Motco now owns 23,228 shares of the medical technology company’s stock valued at $9,122,000 after purchasing an additional 22,515 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Down 0.3%

Shares of SYK stock opened at $355.03 on Tuesday. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The firm has a market cap of $135.77 billion, a P/E ratio of 47.02, a PEG ratio of 2.66 and a beta of 0.94. The company has a 50 day moving average of $373.91 and a 200-day moving average of $381.34. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19.

Stryker (NYSE:SYK) last released its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same period last year, the business posted $2.87 earnings per share. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Sell-side analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Insider Activity

In related news, insider Viju Menon sold 500 shares of Stryker stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider directly owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the sale, the director owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. This represents a 9.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 520,500 shares of company stock worth $184,803,065. Insiders own 5.90% of the company’s stock.

Analysts Set New Price Targets

SYK has been the topic of a number of recent research reports. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Wells Fargo & Company raised their price target on shares of Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. Rothschild Redb raised Stryker to a “hold” rating in a research note on Thursday, September 18th. Weiss Ratings cut Stryker from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday. Finally, UBS Group set a $408.00 price target on Stryker in a research report on Monday, October 13th. Thirteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and a consensus price target of $433.37.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.